ECSP088229A - Derivados de pirazolona como inhibidores de 11-beta hsd1 - Google Patents

Derivados de pirazolona como inhibidores de 11-beta hsd1

Info

Publication number
ECSP088229A
ECSP088229A EC2008008229A ECSP088229A ECSP088229A EC SP088229 A ECSP088229 A EC SP088229A EC 2008008229 A EC2008008229 A EC 2008008229A EC SP088229 A ECSP088229 A EC SP088229A EC SP088229 A ECSP088229 A EC SP088229A
Authority
EC
Ecuador
Prior art keywords
pirazolona
inhibitors
derivatives
beta hsd1
hsd1
Prior art date
Application number
EC2008008229A
Other languages
English (en)
Inventor
Bernd Kuhn
Kurt Amrein
Daniel Hunziker
Alexander V Mayweg
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088229A publication Critical patent/ECSP088229A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la fórmula así como las sales y los ésteres farmacéuticamente aceptables de los mismos, en la que de R1 a R4 tienen los significados definidos en la reivindicación 1, pueden utilizarse en forma de composiciones farmacéuticas.
EC2008008229A 2005-08-31 2008-02-27 Derivados de pirazolona como inhibidores de 11-beta hsd1 ECSP088229A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05107970 2005-08-31

Publications (1)

Publication Number Publication Date
ECSP088229A true ECSP088229A (es) 2008-03-26

Family

ID=37729936

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008229A ECSP088229A (es) 2005-08-31 2008-02-27 Derivados de pirazolona como inhibidores de 11-beta hsd1

Country Status (22)

Country Link
US (1) US7652057B2 (es)
EP (1) EP1924562A2 (es)
JP (1) JP5073664B2 (es)
KR (1) KR100982088B1 (es)
CN (1) CN101243050B (es)
AR (1) AR055145A1 (es)
AU (1) AU2006286646B2 (es)
BR (1) BRPI0615039A2 (es)
CA (1) CA2618840C (es)
CR (1) CR9703A (es)
EC (1) ECSP088229A (es)
IL (1) IL189186A0 (es)
MA (1) MA29775B1 (es)
MX (1) MX2008002583A (es)
MY (1) MY145464A (es)
NO (1) NO20080554L (es)
NZ (1) NZ565536A (es)
RU (1) RU2407737C2 (es)
TW (1) TWI332949B (es)
UA (1) UA90742C2 (es)
WO (1) WO2007025880A2 (es)
ZA (1) ZA200801444B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428467B2 (en) 2008-11-20 2016-08-30 Northwestern University Selective calcium channel antagonists
US10167263B2 (en) * 2008-11-20 2019-01-01 Northwestern University Treatment of amyotrophic lateral sclerosis
US9145424B2 (en) 2008-11-20 2015-09-29 Northwestern University Treatment of amyotrophic lateral sclerosis
ES2423668T3 (es) * 2009-05-22 2013-09-23 Abbvie Inc. Moduladores de receptores 5-HT y métodos de uso de los mismos
WO2011051958A1 (en) 2009-10-30 2011-05-05 E.I. Du Pont De Nemours And Company Fungicidal pyrazolones
WO2011146089A1 (en) * 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
EP2881388A1 (en) 2013-12-09 2015-06-10 Basf Se Pyrazolone compounds having herbicidal activity
EP2881387A1 (en) 2013-12-09 2015-06-10 Basf Se Pyrazolone compounds having herbicidal activity
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
WO2019048988A1 (en) 2017-09-08 2019-03-14 Pi Industries Ltd. Novel fungidal heterocyclic compounds
BR112020004356A2 (pt) 2017-09-08 2020-12-01 Pi Industries Ltd. novos compostos heterocíclicos fungicidas
JP7838792B2 (ja) * 2019-04-17 2026-04-01 ポンティフィカ ウニベルシダッド カトリカ デ チリ 酵素１１－ベータ脱水素酵素１型（１１β－ＨＳＤ１）の還元活性の有効かつ選択的な阻害剤としての使用に適した、アダマンチルオキサジアゾールの誘導体、ならびにそれらの薬学的に許容される溶媒和物、水和物および塩、それらを含む薬学的組成物、合成方法
CN113527207B (zh) * 2020-04-22 2023-06-06 常州强力电子新材料股份有限公司 乙氧基/丙氧基改性的吡唑啉有机物、其应用、光固化组合物及光刻胶
CN112375072B (zh) * 2020-09-28 2021-05-28 上海长征富民金山制药有限公司 吡唑啉酮衍生物、注射剂及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731473A (en) * 1956-01-17 New pyrazolone derivatives
DE668628C (de) * 1935-12-08 1938-12-07 Beiersdorf & Co A G P Verfahren zur Darstellung von Alkyl- und Aralkylabkoemmlingen der 3,4-Cyclotetramethylen-1-aryl-5-pyrazolone
JPS609752B2 (ja) * 1979-11-09 1985-03-12 東邦新薬株式会社 新規な２−アセトキシベンズアミド誘導体、その製法及びそれを有効成分とする医薬
DE4415484A1 (de) 1994-05-03 1995-11-09 Basf Ag Verfahren zur Herstellung von 1-(Het)aryl-3-hydroxy-pyrazolen
US5663365A (en) 1996-10-29 1997-09-02 Japan Hydrazine Co., Ltd. Process for the preparation of pyrazolones
DE69805909T2 (de) 1997-04-10 2002-09-26 Pfizer Inc., New York Fluorosubstituierte Adamantan-Derivate
TW536387B (en) 1998-04-23 2003-06-11 Sumitomo Chemical Co Pyrazolinone compound
EP1213296B1 (en) * 1999-08-31 2004-04-14 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
SK287786B6 (sk) * 2000-12-28 2011-09-05 Kissei Pharmaceutical Co., Ltd. Glukopyranosyloxypyrazolový derivát, farmaceutická kompozícia alebo kombinácia s jeho obsahom a ich použitie
BRPI0313290B1 (pt) * 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
WO2004024705A1 (ja) * 2002-09-10 2004-03-25 Takeda Pharmaceutical Company Limited ５員複素環化合物
WO2004056324A2 (en) 2002-12-19 2004-07-08 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
GB0306718D0 (en) * 2003-03-24 2003-04-30 Sterix Ltd Compound
EP1653949A4 (en) 2003-08-07 2009-04-22 Merck & Co Inc PYRAZOL CARBOXAMIDE AS AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1
GB2637773A (en) * 2024-02-05 2025-08-06 Nokia Technologies Oy Access traffic steering, switching, splitting (ATSSS) between access paths

Also Published As

Publication number Publication date
UA90742C2 (en) 2010-05-25
WO2007025880A3 (en) 2007-05-03
MX2008002583A (es) 2008-03-18
WO2007025880A2 (en) 2007-03-08
KR100982088B1 (ko) 2010-09-13
NO20080554L (no) 2008-03-14
CR9703A (es) 2008-02-20
KR20080031482A (ko) 2008-04-08
CN101243050B (zh) 2012-07-04
EP1924562A2 (en) 2008-05-28
RU2407737C2 (ru) 2010-12-27
IL189186A0 (en) 2008-06-05
TWI332949B (en) 2010-11-11
NZ565536A (en) 2011-03-31
RU2008111971A (ru) 2009-10-10
ZA200801444B (en) 2008-12-31
CA2618840C (en) 2011-07-05
AU2006286646B2 (en) 2010-09-23
US7652057B2 (en) 2010-01-26
TW200740764A (en) 2007-11-01
MY145464A (en) 2012-02-15
AR055145A1 (es) 2007-08-08
MA29775B1 (fr) 2008-09-01
CA2618840A1 (en) 2007-03-08
US20070049574A1 (en) 2007-03-01
CN101243050A (zh) 2008-08-13
HK1123295A1 (en) 2009-06-12
JP2009506089A (ja) 2009-02-12
AU2006286646A1 (en) 2007-03-08
BRPI0615039A2 (pt) 2011-04-26
JP5073664B2 (ja) 2012-11-14

Similar Documents

Publication Publication Date Title
ECSP088082A (es) Derivados de piridazina
CR9703A (es) Derivados de pirazolona
ECSP088549A (es) Nuevos derivados de pirrol fusionado
MY138941A (en) Aryl-pyridine derivatives
ECSP11011555A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
UY31189A1 (es) Compuestos heterocíclicos
UY30500A1 (es) Compuestos de azabencimidazolilo
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
CR20110219A (es) Ácidos naftilacéticos
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
PA8791801A1 (es) Compuestos de pirazol
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
MX2010005824A (es) Derivados de aminotiazol.
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
AR063027A1 (es) Derivados de sulfonamida
UY30476A1 (es) Noveles compuestos derivados n-sustituidos de la 3-oxoisoindolin-1-carboxamida, sus sales aceptables, composiciones farmaccuticas y aplicaciones.
UY27930A1 (es) Derivados de tiazol
UY31000A1 (es) Oxoisoxazoles como inhibidores de lipasas y fosfolipasas
UY27975A1 (es) Derivados de indolilo
AR048589A1 (es) Derivados de pirrolidina -3,4-dicarboxamida
UY30001A1 (es) Alquilsulfonamida quinolinas
ECSP099584A (es) Derivados de ciclohexil-amida del ácido aril-carboxílico